生物制剂市场研究

---

In the fast-paced world of biologics, staying ahead of the curve is crucial. Biologics market research provides the data and insights necessary for businesses to thrive.

您是否希望在动态生物制剂领域获得竞争优势？ 生物制剂市场研究提供了有关市场趋势、监管环境和竞争动态的重要见解。这些见解使公司能够制定有效的战略，优化运营并实现生物制剂市场的可持续增长。

什么是生物制剂？

生物制品包括血液、疫苗、体细胞和组织。基因治疗、血液成分和重组治疗性蛋白质也属于这一范畴。生物制剂来自这些产品的蛋白质、糖或核酸。它们可以是这些物质的复杂混合物，也可以是组织和细胞等生物实体。大多数生物制剂是复合混合物，不易识别。在这方面，它们与大多数药物不同。普通药物来自化学合成；制造商知道它们的结构。

生物制剂是目前最先进的治疗方法之一。医生使用生物制剂治疗多种疾病和病症。生物制剂的医疗用途包括：

• 类风湿关节炎
• 各种癌症
• 克罗恩病
• 心脏病发作
• 多发性硬化症
• 狼疮
• 慢性偏头痛
• 贫血
• 过敏性哮喘
• 囊性纤维化

Biologics Market Research: How Leading Manufacturers Win in Specialty Therapeutics

Biologics now drive the majority of new specialty pharma revenue, and the firms gaining share share one trait: disciplined intelligence. Biologics market research separates teams that price into resistance from teams that secure formulary wins on launch.

The category rewards precision. Molecules compete on indication-level efficacy, payer evidence, injection device experience, and cold chain reliability. Generic frameworks miss this. The winners commission intelligence built around the mechanism of action, the prescriber decision tree, and the payer evidence threshold for each target indication.

Why Biologics Market Research Demands a Different Operating Model

Small molecule playbooks transfer poorly. Biologics carry manufacturing complexity, narrow patient subpopulations, biomarker-driven prescribing, and biosimilar competitive intelligence requirements that begin years before loss of exclusivity. The intelligence model has to match.

Three structural realities shape the work. Prescribing concentrates among a small set of pulmonologists, rheumatologists, oncologists, or dermatologists per market. Payer access decisions hinge on real-world evidence and HTA submission evidence rather than pivotal trial data alone. Patient adherence depends on device usability, site of care economics, and specialty pharmacy distribution.

SIS International Research has found that competitive position in biologics correlates more tightly with KOL mapping depth and payer value story clarity than with headline efficacy data. Asthma biologics provide a clear example: IL-5 and IgE class entrants with similar clinical profiles separated on prescriber confidence, eosinophil biomarker positioning, and injection site experience rather than absolute exacerbation reduction.

The Intelligence Stack That Drives Biologics Launch Success

High-performing teams build a layered intelligence stack rather than a single tracker. Each layer answers a different commercial question and feeds a different function inside the launch organization.

Source: SIS International Research

The stack matters because the questions arrive sequentially. Indication prioritization governs the trial program. KOL mapping shapes the publication plan. Payer value story drafts begin two years before approval. Patient journey work informs hub services. Biosimilar defense begins at peak sales, not at patent cliff.

Where Conventional Research Falls Short and What Replaces It

Standard syndicated reports estimate market size and rank competitors. They rarely reveal why a pulmonologist switched from omalizumab to dupilumab in moderate-to-severe atopic dermatitis with comorbid asthma, or why a German sickness fund tightened prior authorization on a specific IL-5 inhibitor. Those answers come from primary work with the actual decision makers.

Leading manufacturers fund three categories of primary intelligence the syndicated reports cannot replicate. Structured specialist interviews across the US, Germany, Japan, and the UK quantify switching triggers and unmet need by line of therapy. Payer dossier reviews simulate HTA submission evidence against the live reference cases. Patient ethnography captures injection experience, caregiver burden, and the operational pain points that drive discontinuation.

In structured expert interviews conducted by SIS International with senior pulmonologists and allergists across the US, Germany, and Japan, prescriber preference inside the IL-5 class shifted on three non-clinical factors: dosing interval, autoinjector reliability, and the speed of specialty pharmacy fulfillment. Headline efficacy was treated as table stakes once a molecule cleared the eosinophil threshold.

The Global Dimension: Why Multi-Country Design Compounds Returns

Biologics commercialize across regulatory regimes that price and reimburse differently. The FDA, EMA, PMDA, MHRA, NMPA, and ANVISA evaluate the same molecule against different evidence bars. A research design that treats the US as the anchor and bolts on country supplements produces blind spots in the markets that often determine global net price.

Germany’s AMNOG benefit assessment, England’s NICE appraisal, and Japan’s Chuikyo pricing all set reference points other payers watch. France’s transparency commission scoring shapes EU pricing corridors. Disciplined teams design the global research program backward from the toughest HTA submission evidence requirement, not forward from the US label.

SIS International’s biologics work across the US, EU5, Japan, and emerging Asia has shown that launch sequencing decisions made on US-only research overestimate ex-US net price by meaningful margins. Multi-country payer panels run in parallel produce a defensible price corridor and identify the indications where evidence generation will move the access needle.

The SIS Biologics Intelligence Framework

The framework below organizes the work most Fortune 500 biopharma teams now commission across the lifecycle. It is method-led rather than topic-led, which keeps the intelligence tied to actual launch and defense decisions.

Source: SIS International Research

What Separates the Manufacturers That Win Share

The pattern is consistent across asthma, atopic dermatitis, IBD, plaque psoriasis, and oncology biologics. Manufacturers that gain share treat market research as a continuous instrument rather than a launch event. They refresh KOL mapping quarterly, rerun payer value story testing after every competitive label expansion, and run patient ethnography on a rolling cycle.

They also integrate the intelligence. Medical affairs, market access, marketing, and competitive intelligence read from the same evidence base. The integration prevents the common failure mode in which the brand team prices for a value story the payer team has already abandoned in dossier negotiations.

Biologics market research, done with this discipline, is the single highest-leverage commercial investment a specialty manufacturer makes. The ratio of research spend to peak sales protected is favorable across every major class SIS has profiled.

Where Senior Teams Take This Next

The teams getting biologics market research right are now extending the model into bispecifics, cell and gene therapies, and the next biosimilar wave. The methods scale. The discipline of asking the right question at the right lifecycle stage, to the right specialist or payer, in the right country, transfers cleanly into the modalities that will define the next decade of specialty therapeutics.

关于 SIS 国际

SIS 国际 提供定量、定性和战略研究。我们提供决策所需的数据、工具、战略、报告和见解。我们还进行访谈、调查、焦点小组和其他市场研究方法和途径。 联系我们 为您的下一个市场研究项目提供帮助。